29 April 2021 | News
Dishman Carbogen Amcis announces that its subsidiary, Carbogen Amcis AG has entered into a co-investment agreement to create a state-of-the art facility to produce commercial antibody-drug-conjugate API
Photo Credit: Dishman Carbogen Amcis
The company’s subsidiary, Carbogen Amcis AG, pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a joint funding agreement with a longstanding Japan-based customer to build a site extension at the Bubendorf site in Switzerland.
The expansion will be created adjacent to an existing manufacturing facility on the Bubendorf Switzerland Site. This important expansion will incorporate a new production line comprising of two 850 L reactors and one agitated filter drier. The facility is designed for highly potent manufacturing up to category 4 (OEL of 1 µg/m³ and lower).
“We are grateful for the trust our customer has placed in us by deciding to support the Bubendorf site extension. Their investment will enable the creation of a state-of-the art facility that will benefit them directly,” said Pascal Villemagne, VP sales and Marketing, CARBOGEN AMCIS. “This joint investment cements our working relationship over the long term and lays the foundation for a promising future.”
CARBOGEN AMCIS will produce exclusively for the signatory customer a complex highly potent drug component for a commercial antibody-drug-conjugate API entering the global supply chain network.
“The production of this intermediate involves five Dishman Carbogen Amcis facilities around the world: three sites in Switzerland (Bubendof, Hunzenschwil and Aarau), one in the UK (Manchester) and one in China (Shanghai). The highly potent production element will take place in Bubendorf, in the new building extension.” commented Mark Griffiths, Director, Dishman Carbogen Amcis Limited.
Currently, the planning phase for the building extension is underway and the Company expects to commence operations in autumn 2022.